Psilocybin
Mydecine Loss Rate Increases, Only C$10k Left On Hand
The Canadian psychedelics company reported a loss of C$7.6 million for the first quarter.
The post Mydecine Loss Rate Increases, Only C$10k Left On Hand…
Canadian psychedelics company Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: ONFA) was left with just over C$10,000 in the bank after losing C$7.65 million in the first three months of 2023, contrasted with C$10.2 million in liabilities the company was carrying and C$2.2 million in assets.
The losses were a substantial increase from Mydecine’s cash burn rate in 2022; the company lost C$5.63 million for the same period a year prior and C$11.56 million for all of last year.
The company has struggled to bring psilocybin-based therapeutic products to market in order to assist patients who deal with addiction and post-traumatic stress disorder, since its launch in 2020.
Mydecine said in its earnings report that it’s continuing its focus on “innovative medications for target indications with high mortality rates that have lacked innovation for decades and are controlled by dominant corporations.”
The company said trials for a “psilocybin-derived smoking cessation drug” in conjunction with Johns Hopkins University and funded by the U.S. National Institute on Drug Abuse, are still ongoing.
Mydecine also is continuing development on an MDMA-based drugs to treat anxiety and pain. And it’s using artificial intelligence in research at the University of Alberta to develop more psychedelics medicines.
The post Mydecine Loss Rate Increases, Only C$10k Left On Hand appeared first on Green Market Report.
psilocybin mdma anxiety psychedelics otc deal mydecine innovations group mydecine research
Reunion Neuroscience Inc. Announces $103 Million Series A Financing Co-Led by MPM BioImpact and Novo Holdings
Compass Pathways establishes research collaboration with Mindful Health Solutions to inform the development of a scalable and cost-effective delivery model for investigational COMP360 psilocybin treatment
MindBio Therapeutics Announces Landmark Women’s Health CNS Drug Trials
MindBio Therapeutics Announces Landmark Women’s Health CNS Drug Trials
Compass Pathways establishes research collaboration with Mindful Health Solutions to inform the development of a scalable and cost-effective delivery model for investigational COMP360 psilocybin treatment
Reunion Neuroscience Inc. Announces $103 Million Series A Financing Co-Led by MPM BioImpact and Novo Holdings
GH Research advances depression therapies, burns cash
PharmAla Launches Prescriber’s Portal for Medical Professionals Focused on MDMA Therapy
MindBio Therapeutics Scientists Present Landmark Women’s Health Trials, Company to Release Phase 2A Depression Trial Secondary Data This Month
-
Psychedelics1 week agoAlgernon NeuroScience and the Centre for Human Drug Research to Present DMT Phase 1 Stroke Clinical Data at the Interdisciplinary Conference on Psychedelic Research June 6 – 8th, 2024
-
Psychedelics1 week agoatai Life Sciences Announces Dosing of First Patient in Part 2 of Beckley Psytech’s Phase 2a Study Exploring BPL-003 Adjunctive to SSRIs in Patients with Treatment Resistant Depression
-
Law & Regulation1 week agoTryp Therapeutics, Exopharm merger approved by shareholders
-
Psychedelics1 week ago
MindBio Landmark Sleep Research Published in Prestigious Nature Portfolio Journal Translational Psychiatry
-
LSD1 week agoThe First Wave of Blotter Acid Inspired Trippy Psychedelic Art
-
Law & Regulation1 week ago
Adastra reports record sales in 2023, but remains in the red
-
Psilocybin7 days agoPsychedelic Underground Celebrated in San Francisco on Bicycle Day Weekend
-
Psychedelics5 days ago
Compass Pathways and Journey Clinical Establish Research Collaboration Agreement To Inform the Training of Healthcare Providers and Delivery Model for COMP360 Psilocybin Treatment, If Approved for Treatment-Resistant Depression
